Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 10:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 2,840 matching trials from the live ClinicalTrials.gov search.
Conditions
Melanoma (Skin)
Interventions
NY-ESO-1 peptide vaccine, aldesleukin, filgrastim, incomplete Freund's adjuvant, therapeutic autologous lymphocytes, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
Bethesda, Maryland
Conditions
Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Galunisertib, Laboratory Biomarker Analysis, Paclitaxel
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Breast Cancer
Interventions
filgrastim, carboplatin, cyclophosphamide, mesna, paclitaxel, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1994
U.S. locations
3
States / cities
Indianapolis, Indiana • St Louis, Missouri • Memphis, Tennessee
Conditions
Renal Cell Cancer, Melanoma, Non-Small-Cell Lung Cancer, Hepatocellular Cancer, Bladder Cancer, Sarcoma, Head and Neck Cancer, Colorectal Cancer, Ovarian Cancer, Squamous Cell Carcinoma
Interventions
PF-07263689, Sasanlimab
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Duarte, California • New York, New York
Conditions
Melanoma
Interventions
Relatlimab, Nivolumab, Relatlimab + Nivolumab
Drug
Lead sponsor
John Kirkwood
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Laboratory Biomarker Analysis, Nab-paclitaxel, Questionnaire Administration
Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
4
States / cities
Duarte, California • Lancaster, California • South Pasadena, California + 1 more
Conditions
Advanced Cancer
Interventions
LY3475070, Pembrolizumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
7
States / cities
Denver, Colorado • Lake Mary, Florida • Grand Rapids, Michigan + 4 more
Conditions
Breast Cancer, Hematologic Neoplasms
Interventions
AUY922 2 mg/m2
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
7
States / cities
Los Angeles, California • Augusta, Georgia • Boston, Massachusetts + 4 more
Conditions
Metastatic Breast Cancer
Interventions
DB-1303/BNT323, Capecitabine, Paclitaxel, Nab-paclitaxel
Drug
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
44
States / cities
Tucson, Arizona • Fullerton, California • Los Angeles, California + 39 more
Conditions
Breast Cancer
Interventions
vepdegestrant, Samuraciclib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
19
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 9 more
Conditions
Sarcoma, Melanoma, Epithelial Malignancies, Pleural Malignancies
Interventions
Cyclophosphamide, Allogenic tumor Cell Vaccine (K562), Celecoxib
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Breast Cancer
Interventions
Multicomponent Adherence Intervention
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 99 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Metastatic Breast Cancer
Interventions
Not listed
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Metastatic Breast Cancer
Interventions
Pertuzumab, Trastuzumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
16
States / cities
Tucson, Arizona • Duarte, California • Stanford, California + 13 more
Conditions
Metastases, Brain
Interventions
capecitabine, lapatinib, trastuzumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
17
States / cities
Goodyear, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 14 more
Conditions
Breast Cancer
Interventions
Palbociclib, Aromatase Inhibitor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
779 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, Pancreatic Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Other Solid Tumors, Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma, Indolent B-cell Lymphomas, Non-Hodgkin Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Waldenstrom's Disease, Marginal Zone Lymphoma, Mucosa Associated Lymphoid Tissue, Small Lymphocytic Leukemia
Interventions
CDX-1140, CDX-301, pembrolizumab, Chemotherapy
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
11
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Augusta, Georgia + 7 more
Conditions
Breast Cancer
Interventions
Tobemstomig, Pembrolizumab, Nab-Paclitaxel
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Los Alamitos, California • New York, New York • Charlotte, North Carolina + 1 more
Conditions
Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
PF-08046037, sasanlimab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Denver, Colorado • New Haven, Connecticut • Trumbull, Connecticut + 3 more
Conditions
Breast Cancer, Brain Metastasis, Brain Cancer
Interventions
T-DM1, TMZ
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
HER2-positive Breast Cancer
Interventions
Dendritic Cell (DC1) Vaccine, Trastuzumab, Pepinemab, T-Cell therapy
Biological · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Metastatic Breast Cancer
Interventions
Trastuzumab Deruxtecan
Drug
Lead sponsor
Sun Yat-sen University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
New Haven, Connecticut • Boston, Massachusetts
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Anastrozole, Exemestane, Fulvestrant, Letrozole, Palbociclib, Radiation Therapy, Tamoxifen
Drug · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Atlanta, Georgia • Augusta, Georgia • Columbus, Georgia + 2 more
Conditions
Metastatic Melanoma
Interventions
Temozolomide, Decitabine, Panobinostat
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Iowa City, Iowa